v3.25.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Segment Reporting

Segment Reporting

The Company operates in one business segment in the United States, which includes all activities related to the development of novel therapies across a range of cancers. The Company's chief operating decision-maker is its chief executive officer. The chief operating decision-maker allocates resources based on available cash, cash equivalents and short-term investments. The primary measure of performance reviewed by the chief operating decision-maker is net loss which is compared to the annual budget and quarterly forecasts.

All financial information required for segment reporting that is provided to the chief operating decision-maker is contained within the financial statements and notes to financial statements, with the exception of the disaggregated amounts contained in the table below:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

(in thousands)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Research and development:

 

 

 

 

 

 

 

 

 

 

 

 

Salaries and staff costs

 

$

2,134

 

 

$

1,714

 

 

$

4,103

 

 

$

3,582

 

Stock-based compensation

 

 

672

 

 

 

397

 

 

 

1,187

 

 

 

786

 

Clinical trials, outside services, and lab supplies

 

 

8,306

 

 

 

6,950

 

 

 

15,803

 

 

 

12,202

 

Facilities and other

 

 

468

 

 

 

432

 

 

 

964

 

 

 

931

 

Total research and development

 

$

11,580

 

 

$

9,493

 

 

$

22,057

 

 

$

17,501

 

Selling, general and administrative:

 

 

 

 

 

 

 

 

 

 

 

 

Salaries and staff costs

 

$

849

 

 

$

807

 

 

$

1,775

 

 

$

1,714

 

Stock-based compensation

 

 

1,011

 

 

 

782

 

 

 

1,861

 

 

 

1,517

 

Outside services and professional fees

 

 

1,062

 

 

 

1,167

 

 

 

2,860

 

 

 

2,150

 

Facilities and other

 

 

396

 

 

 

459

 

 

 

836

 

 

 

964

 

Total selling, general and administrative

 

$

3,318

 

 

$

3,215

 

 

$

7,332

 

 

$

6,345

 

Net Loss Per Share

Net Loss Per Share

Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:

 

 

 

June 30,

 

 

 

2025

 

 

2024

 

Options to purchase Common Stock

 

 

11,701,432

 

 

 

8,351,122

 

Warrants to purchase Common Stock

 

 

2,787,714

 

 

 

2,807,353

 

Series A Convertible Preferred Stock

 

 

877

 

 

 

877

 

 

 

14,490,023

 

 

 

11,159,352

 

Investment Securities

Investment Securities

Investment transactions are recorded on the trade date, and purchases of investments that are settled after the balance sheet date are included in accrued liabilities. All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months.

Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive loss. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in interest income, net, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.

Recent Accounting Pronouncement Not Yet Adopted

Recent Accounting Pronouncement Not Yet Adopted

In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024 and for private businesses for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.

In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” The update requires disclosure of specific expense categories in the notes to the financial statements at interim and annual reporting periods. The update requires disaggregated information about certain prescribed expense categories underlying any relevant income statement expense caption. The amendments in this update are effective for public entities for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The amendments may be adopted either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statement disclosures.